Agenus reports long-term survival data for BOT+BAL in refractory MSS mCRC at SITC 2026

Agenus presented data at the SITC 2026 meeting showing that more than 50% of patients with refractory MSS metastatic colorectal cancer treated with botensilimab plus balstilimab (BOT+BAL) achieved long-term survival, from its Phase 1b C-800-01 trial in heavily pretreated patients without active liver metastases.

Detected & updated continuously · Source: Nebula